NASDAQ: ATAI
Atai Life Sciences Nv Stock

$1.50+0.09 (+6.38%)
Updated Apr 30, 2025
ATAI Price
$1.50
Fair Value Price
$0.05
Market Cap
$297.46M
52 Week Low
$1.03
52 Week High
$2.57
P/E
-1.61x
P/B
2.56x
P/S
691.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$308.00k
Earnings
-$149.27M
Gross Margin
100%
Operating Margin
-47,565.26%
Profit Margin
-48,464%
Debt to Equity
0.37
Operating Cash Flow
-$82M
Beta
1.42
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A

ATAI Overview

Atai Life Sciences N.V. is a clinical-stage biopharmaceutical company developing various therapeutic candidates that focus on various mental health disorders including depression, substance use disorder, and anxiety. The company's pipeline includes PCN-101, RL-007, DMX-1002, GRX-917, NN-101, VLS-01, EMP-01, RLS-01, DMX-1001, and others. Formerly known as Adripa Holding B.V., Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ATAI's potential to beat the market

FStrong Sell
  • Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ATAI
Ranked
#428 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ATAI news, forecast changes, insider trades & much more!

ATAI News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ATAI ($1.50) is overvalued by 2,796.66% relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ATAI ($1.50) is not significantly undervalued (2,796.66%) relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATAI due diligence checks available for Premium users.

Valuation

ATAI fair value

Fair Value of ATAI stock based on Discounted Cash Flow (DCF)

Price
$1.50
Fair Value
$0.05
Overvalued by
2,796.66%
ATAI ($1.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATAI ($1.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ATAI price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.61x
Industry
-162.28x
Market
29.18x

ATAI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.56x
Industry
4.45x
ATAI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ATAI's financial health

Profit margin

Revenue
-$5.0k
Net Income
-$39.0M
Profit Margin
779,160%
ATAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ATAI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$159.4M
Liabilities
$42.8M
Debt to equity
0.37
ATAI's short-term assets ($80.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATAI's short-term assets ($80.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATAI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ATAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$24.3M
Investing
$6.6M
Financing
$154.0k
ATAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ATAI vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ATAIF$297.46M+6.38%-1.61x2.56x
PHATD$298.74M-1.61%-0.81x-1.18x
GLUEC$302.01M+2.51%-5.01x1.35x
AURAD$292.81M+4.86%-3.33x1.93x
ATXSD$291.20M+0.78%-3.07x0.91x

Atai Life Sciences Nv Stock FAQ

What is Atai Life Sciences Nv's quote symbol?

(NASDAQ: ATAI) Atai Life Sciences Nv trades on the NASDAQ under the ticker symbol ATAI. Atai Life Sciences Nv stock quotes can also be displayed as NASDAQ: ATAI.

If you're new to stock investing, here's how to buy Atai Life Sciences Nv stock.

What is the 52 week high and low for Atai Life Sciences Nv (NASDAQ: ATAI)?

(NASDAQ: ATAI) Atai Life Sciences Nv's 52-week high was $2.57, and its 52-week low was $1.03. It is currently -41.52% from its 52-week high and 45.63% from its 52-week low.

How much is Atai Life Sciences Nv stock worth today?

(NASDAQ: ATAI) Atai Life Sciences Nv currently has 198,306,455 outstanding shares. With Atai Life Sciences Nv stock trading at $1.50 per share, the total value of Atai Life Sciences Nv stock (market capitalization) is $297.46M.

Atai Life Sciences Nv stock was originally listed at a price of $19.45 in Jun 18, 2021. If you had invested in Atai Life Sciences Nv stock at $19.45, your return over the last 3 years would have been -92.29%, for an annualized return of -57.43% (not including any dividends or dividend reinvestments).

How much is Atai Life Sciences Nv's stock price per share?

(NASDAQ: ATAI) Atai Life Sciences Nv stock price per share is $1.50 today (as of Apr 30, 2025).

What is Atai Life Sciences Nv's Market Cap?

(NASDAQ: ATAI) Atai Life Sciences Nv's market cap is $297.46M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Atai Life Sciences Nv's market cap is calculated by multiplying ATAI's current stock price of $1.50 by ATAI's total outstanding shares of 198,306,455.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.